The treatment of colorectal cancer during pregnancy: Cytotoxic chemotherapy and targeted therapy challenges

Jane E. Rogers; Arvind Dasari; Cathy Eng

doi:10.1634/theoncologist.2015-0362

The treatment of colorectal cancer during pregnancy: Cytotoxic chemotherapy and targeted therapy challenges

Jane E. Rogers, Arvind Dasari, Cathy Eng

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy.

Original language	English (US)
Pages (from-to)	563-570
Number of pages	8
Journal	Oncologist
Volume	21
Issue number	5
DOIs	https://doi.org/10.1634/theoncologist.2015-0362
State	Published - Mar 21 2016

Keywords

Antineoplastics
Colorectal neoplasms
Monoclonal antibodies
Pregnancy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1634/theoncologist.2015-0362

Cite this

@article{be27a69de39a42e283d4815cb486912d,

title = "The treatment of colorectal cancer during pregnancy: Cytotoxic chemotherapy and targeted therapy challenges",

abstract = "Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy.",

keywords = "Antineoplastics, Colorectal neoplasms, Monoclonal antibodies, Pregnancy",

author = "Rogers, {Jane E.} and Arvind Dasari and Cathy Eng",

note = "Publisher Copyright: {\textcopyright} AlphaMed Press 2016.",

year = "2016",

month = mar,

day = "21",

doi = "10.1634/theoncologist.2015-0362",

language = "English (US)",

volume = "21",

pages = "563--570",

journal = "Oncologist",

issn = "1083-7159",

publisher = "AlphaMed Press",

number = "5",

}

TY - JOUR

T1 - The treatment of colorectal cancer during pregnancy

T2 - Cytotoxic chemotherapy and targeted therapy challenges

AU - Rogers, Jane E.

AU - Dasari, Arvind

AU - Eng, Cathy

N1 - Publisher Copyright: © AlphaMed Press 2016.

PY - 2016/3/21

Y1 - 2016/3/21

N2 - Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy.

AB - Cancer diagnosed during pregnancy has increased because of delayed child-bearing and the known occurrence of age dependent malignancies. Cases of colorectal cancer (CRC) in pregnancy have recently been reported. With the expected rise in CRC diagnosed in young adults coupled with the current trend of delayed child-bearing, CRC during pregnancy is likely to increase. Treating pregnant women with CRC by using antineoplastics presents a dilemma because there are many unknowns to guide treatment decisions. We review the issues regarding the use of 10 CRC-approved agents in pregnancy.

KW - Antineoplastics

KW - Colorectal neoplasms

KW - Monoclonal antibodies

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84966340226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966340226&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2015-0362

DO - 10.1634/theoncologist.2015-0362

M3 - Article

C2 - 27000464

AN - SCOPUS:84966340226

SN - 1083-7159

VL - 21

SP - 563

EP - 570

JO - Oncologist

JF - Oncologist

IS - 5

ER -

The treatment of colorectal cancer during pregnancy: Cytotoxic chemotherapy and targeted therapy challenges

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this